MRD negativity in MM patients correlates with improved survival, suggesting its potential as a surrogate marker for survival outcomes. Novel therapeutics complicate the assessment of PFS and OS, ...
SAN DIEGO--(BUSINESS WIRE)--Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, has introduced MRDVision, a minimal residual disease (MRD) detection solution showcasing a limit of ...
Panelists discuss how minimal residual disease (MRD) status can guide post-transplant treatment decisions, particularly for high-risk patients who don’t achieve MRD negativity and patients considering ...
NEW ORLEANS -- Consolidation chemotherapy with blinatumomab (Blincyto) improved overall survival (OS) in patients with newly diagnosed measurable residual disease (MRD)-negative B-lineage acute ...
RIO DE JANEIRO — A quadruplet induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in the treatment of newly diagnosed multiple myeloma (MM) shows a notably high ...
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions. The ...
Adaptive Biotechnologies Corporation announced that its clonoSEQ® test for measurable residual disease (MRD) will be prominently featured in 30 presentations at the upcoming American Society of ...
Personalis has high upside potential if its MRD test gains Medicare reimbursement, but current revenue and margins are under pressure. The company faces declining pharma revenue, sustained cash burn, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback